1 Part 1 Importance of Identifying and Managing Postprandial Hyperglycemia An Educational Service from G LYCO M ARK G LYCO M ARK is a registered trademark.

Slides:



Advertisements
Similar presentations
THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)
Advertisements

GLYCOMARK A NEW BLOOD TEST FOR PPG.
Aggressive Hyperglycemia Management. Significant hospital hyperglycemia requires close follow-up Previously diagnosed diabetes and elevated A1C Without.
Canadian Diabetes Association Clinical Practice Guidelines Acute Coronary Syndromes and Diabetes Chapter 26 Jean-Claude Tardif, Phillipe L. L’Allier, David.
Diabetes in Pregnancy Screening.
TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.
Diabetes Mellitus Type 2
Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.
Canadian Diabetes Association 2013 Clinical Practice Guidelines Targets for Glycemic Control Chapter 8 S. Ali Imran, Rémi Rabasa-Lhoret, Stuart Ross.
ACCORD - Action to Control Cardiovascular Risk in Diabetes ADVANCE - Action in Diabetes to Prevent Vascular Disease VADT - Veterans Administration Diabetes.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Therapy of Type 2 Diabetes Mellitus: UPDATE
BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.
Diabetes Mellitus Ibrahim Sales, Pharm.D. Assistant Professor of Clinical Pharmacy King Saud University
IDC Diabetes Update: Recent Research and Impact on Diabetes Management Type 1 DiabetesType 1 Diabetes –Post DCCT findings--improving glycemic control and.
Blood glucose: is lower better for diabetic patients?
Glycemic Control for myocardial infraction. Why??????
Clinical Outcomes with Newer Antihyperglycemic Agents
Session II: Glycemic control, when the lower is not the better Strict glycemic control and cardiovascular diseases Stefano Genovese Diabetologia e Malattie.

Modern Management of Cholesterol in the High-Risk Patient.
1 NHLBI/NEI National Institutes of Health NHLBI/NEI National Institutes of Health.
Cardiovascular Disease & Mortality in Diabetes Stephen Fava MD, MRCP(UK), FEFIM, FACP, FRCP (Lond), MPhil (Malta), PhD (Exeter) Consultant Physician, Diabetologist.
Leveraging Weight Loss in the Treatment of Type 2 Diabetes Part 1 of 4.
PPAR  activation Clinical evidence. Evolution of clinical evidence supporting PPAR  activation and beyond Surrogate outcomes studies Large.
Lower the better; the case for glucose Professor Taner DAMCI Istanbul University Cerrahpaşa Medical School, TURKEY.
ORIGIN Outcome Reduction with an Initial Glargine Intervention (ORIGIN) Trial Overview Large international randomized controlled trial in patients with.
Consider testing if person is: – Overweight or obese with additional risk factor for diabetes – Age 45 or older Obtain: A1C or FPG or 2-hour plasma glucose.
Hyperglycemia and Acute Coronary Syndromes. Cardiovascular disease and diabetes Bell DSH. Diabetes Care. 2003;26: Centers for Disease Control.
Glycemic Control: When the Lower is Not the “Better”?
Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.
1 Part 2 Routinely Identifying Postprandial Hyperglycemia - Challenges & Tools An Educational Service from G LYCO M ARK G LYCO M ARK is a registered trademark.
A Diabetes Outcome Progression Trial
1 Part 4 1,5-Anhydroglucitol Outcomes Research and Link to Complications An Educational Service from G LYCO M ARK G LYCO M ARK is a registered trademark.
Diabetes Update Division of Endocrinology Department of Medicine Wayne State University Medical School Detroit, Michigan Part 1 of 3.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015
An Educational Service from GlycoMark
Impact of Diabetes on Cardiovascular Risk C.Richard Conti M.D. MACC Oct 16,2004 GWICC Beijing, PRC.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015
Demystifying Cardiovascular Safety of Sulfonylurea.
Clinical Outcomes with Newer Antihyperglycemic Agents FDA-Mandated CV Safety Trials 1.
An initiative of South Asian Federation of Endocrine Societies (SAFES)
Long-term Cardiovascular Effects of 4.9 Years of Intensive Blood Pressure Control in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk.
Part 3. Diabetes Report Card: HbA 1c Levels in the United States Hoerger TJ, et al. Diabetes Care. 2008;31: Patients (%) HbA 1c (%)
Rosuvastatin 10 mg n=2514 Placebo n= to 4 weeks Randomization 6weeks3 monthly Closing date 20 May 2007 Eligibility Optimal HF treatment instituted.
DIABETES INSTITUTE JOURNAL CLUB CARINA SIGNORI, D.O., M.P.H. DECEMBER 15, 2011 Atherothrombosis intervention in metabolic syndrome with low HDL/High Triglycerides:
Voglibose in PPHG Dr. Mohammed Riyaz
Carina Signori, D.O., M.P.H. Penn State Hershey Medical Center Ceriello, Antonio. Diabetes Care August 2010;33,8.
Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Effectiveness of Pharmacist Interventions on.
R1 강민혜 / prof. 전숙. Introduction Patients with type 2 diabetes have a greatly increased risk of cardiovascular events. The morbidity and mortality related.
Measures of Hyperglycemia Random plasma glucose (RPG)—without regard to time of last meal Fasting plasma glucose (FPG)—before breakfast Oral glucose tolerance.
Cardiovascular Disease and Antihypertensives The RENAAL Trial Reference Brunner BM, and the RENAAL study group. Effects of losartan on renal and cardiovascular.
Achieving Optimal Glycaemic Control: Can Insulin Deliver?
ACCORD Design and Baseline Characteristics
Pathophysiology and Prevention of Heart Disease in Diabetes Mellitus
Reducing Adverse Outcomes after ACS in Patients with Diabetes Goals
Recent Breakthroughs in Cardiovascular Outcomes Trials in T2DM
Screening and Monitoring
Macrovascular Complications Microvascular Complications
Systolic Blood Pressure Intervention Trial (SPRINT)
366 میلیون نفر در جهان مبتلا به دیابت هستند.
Incidence of CV Events in Subjects With T2D vs the Nondiabetic CAD Population
SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.
Incidence of CV Events in Subjects With T2D vs the Nondiabetic CAD Population
Glycemic control for macrovascular disease in type II diabetes: Evidence and insights from recent trials  Sanjay Rajagopalan  Journal of Indian College.
Strategies for Optimizing Glycemic Control and Cardiovascular Prognosis in Patients With Type 2 Diabetes Mellitus  James H. O'Keefe, MD, Mohammad Abuannadi,
Effects of Niacin on Glucose Control in Patients With Dyslipidemia
Diabetes, prediabetes, and cardiovascular risk: Shifting the paradigm
EMPA-REG OUTCOME: Cumulative incidence of the primary outcome
Many post-MI patients are not receiving optimal therapy
Presentation transcript:

1 Part 1 Importance of Identifying and Managing Postprandial Hyperglycemia An Educational Service from G LYCO M ARK G LYCO M ARK is a registered trademark of GlycoMark, Inc. © GlycoMark, Inc. All rights reserved NOTE: Please see slide notes below each page for study and slide details

2 4 Part Series - Identifying and Managing Postprandial Hyperglycemia (PPH) 1.Importance of identifying and managing postprandial hyperglycemia (PPH) 2.Routinely identifying PPH – challenges and tools 3.Interpretation and clinical use of a new biomarker for PPH 1,5-Anhydroglucitol 4.1,5-Anhydroglucitol outcomes research

3 The Glycemic Triad 1 Postprandial Hyperglycemia day mean glucose Fasting Glucose Baseline/preprandial glucose HbA1C ADA: <7.0% AACE: <6.5% ADA: <180 mg/dL AACE: <140 mg/dL ADA: mg/dL AACE: <110 mg/dL Nearly 40% of patients in “good control” have significant glucose variability 2 1 Monnier et al. Current Diabetes Reports 2008, 8:368–374 2 Bonora et al. Diabetologia, 2006

4 Attaining A1C below 7% is difficult but important DCCT and UKPDS demonstrated every 1% reduction in A1C significantly reduces complications Postmeal glucoses often not available for safe adjustment of fasting vs. prandial medications in patients with similar A1Cs Postprandial hyperglycemia (PPH) has been proven to independently contribute to diabetes complications Gimeno-Orna J, Castro-Alonso F, Boned-Juliani B, Lou-Arnal L. Fasting plasma glucose variability as a risk factor of retinopathy in Type 2 diabetic patients. J Diabetes Complications. 2003;17(2): DCCT Research Group. N Engl J Med. 1993;329: DCCT Research Group, The relationship of glycemic exposure (HbA1C) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 1995;44: DECODE Study Group. Lancet 1999; 354:617–621 5 Hanefeld M, et al., for the DIS Group. Riskfactors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up.Diabetologia 1996;39: Gerich J., Clinical Significance, Pathogenesis and Management of Postprandial Hyperglycemia, Arch Intern Med 2003; 163: Esposito K. Regression of Carotid Atherosclerosis by Control of Postprandial Hyperglycemia in T2DM,Circulation, 2004;110; Cavalot, et al. Postprandial Blood Glucose Is a Stronger Predictor of Cardiovascular Events Than Fasting Blood Glucose inType 2 Diabetes Mellitus, Particularly in Women: Lessons from the San Luigi Gonzaga Diabetes Study, Clin Endocrinol Metab 91: 813–819, Emoto, et al. Effect of 3-Month Repeated Administration of Miglitol on Vascular Endothelial Function in Patients With Diabetes Mellitus and Coronary Artery Disease, J Cardiol 2011

5 Postprandial Hyperglycemia and Coronary Artery Disease Reduction in Coronary Lumen Diameter with each PPG increase Mellen PB et al. Poster Presentation at American Heart Association. 2006

6 Postprandial Hyperglycemia and Relative Risk of Death (regardless of FPG) 126 mg/dL >200 mg/dL <140 Fasting plasma glucose 2-hour plasma glucose Hazard ratio Adjusted for age, center, sex ; 7 year followup study DECODE Study Group. Lancet 1999;354:617–621 N=25,364

7 Impact of Glycemic Variability, Glucose and A1C on Major Adverse Cardiac Events (MACE) After Acute MI Mean Amplitude Glycemic Excursion (MAGE) > 70 mg/dL was more important than A1C or glucose in predicting 1-year MACE (MI, Death, Acute heart failure) after initial AMI G Su, et al., Impact of Admission Glycemic Variability, Glucose, and Glycosylated Hemoglobin on Major Adverse Cardiac Events After Acute Myocardial Infarction, Diabetes Care, January 2013 MAGE > 70 mg/dL MAGE < 70 mg/dL p=0.001 A1C > 6.5% A1C < 6.5% p=0.091 (NS)

8 Fewer Older T2D Experienced a Cardiovascular Event on Prandial Insulin Therapy vs. Basal Therapy Raz, Ceriello, et al. Post Hoc Subgroup Analysis of the HEART2D Trial Demonstrates Lower Cardiovascular Risk in Older Patients Targeting Postprandial Versus Fasting/Premeal Glycemia. Diabetes Care (34), Jul 2011 Prandial Basal Log-rank P = Primary CV Outcomes CV death Non-fatal stroke Non-fatal MI Coronary revascularization Hospitalized acute coronary syndromes

9 Increased PPG (Lower 1,5-AG) Correlates with Increased Carotid Artery Stiffness in Non-Diabetics Intima-media thickness (IMT) p=NS Pulsatility Index (PI) *p<0.05 Watanabe, et al. BMC Cardiovascular Disorders, Relationship between postprandial glucose level and carotid artery stiffness in patients without diabetes or cardiovascular disease, Feb 2013, 13:11 1,5-AG A1C ,5-AG A1C ,5-AG A1C ,5-AG A1C

10 33 Year Survival Depends on Baseline Glucose Tolerance Status using 2 Hour 50 g OGTT Age-adjusted survival over 33 years of follow up was dose- dependent from as low as 83 mg/dL 2 hours post glucose load Normoglycemia <96 mg/dL N=16,826 Years at Risk Survival IGT > mg/dL N=987 T2DM >200 mg/dL N=56 Brunner, et al. Relation Between Blood Glucose and Coronary Mortality Over 33 Years in the Whitehall Study. Diabetes Care 29:26–31, 2006

11 For more information For a listing of postprandial hyperglycemia outcome studies, please visit For a listing of studies about the 1,5-anhydroglucitol biomarker for postprandial hyperglycemia, please visit For a 3-minute overview about the 1,5-anhydroglucitol biomarker, please visit